Scopus Biopharma

Scopus Biopharma PP&E per Employee

The PP&E per Employee of Scopus Biopharma (SCPS) as of Nov 19, 2026 is 174.23 USD. In the previous year, PP&E per Employee was 218.46 USD — a change of -20.25% (lower).

PP&E per Employee

174.23USD

YoY

-20.25%

Last updated:

PP&E per Employee of Scopus Biopharma is 2022 174.23 USD. PP&E per Employee of Scopus Biopharma was 2021 218.46 USD. It decreases by -20.25% lower compared to the previous year.

The Scopus Biopharma PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2019
281.46 USD
Jan 1, 2020
179.15 USD
Jan 1, 2021
218.46 USD
Jan 1, 2022
174.23 USD
The Scopus Biopharma PP&E per Employee history
YEARPP&E per EmployeeYoY
174.23USD-20.25%
218.46USD+21.94%
179.15USD-36.35%
281.46USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

PP&E per Employee of Scopus Biopharma is 174.23 USD in 2022.

PP&E per Employee of Scopus Biopharma changed from 218.46 USD to 174.23 USD, representing a -20.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Scopus Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Scopus Biopharma

All Key Metrics — Scopus Biopharma